Revenio Group Oyj (HEL:REG1V)

Market Cap	334.16M -55.4%
Revenue (ttm)	111.05M +4.4%
Net Income	15.71M -17.7%
EPS	0.59 -17.7%
Shares Out	26.61M
PE Ratio	21.35
Forward PE	14.69
Dividend	0.44 (3.50%)
Ex-Dividend Date	n/a

Volume	45,373
Open	12.82
Previous Close	12.76
Day's Range	12.52 - 12.98
52-Week Range	12.44 - 29.10
Beta	0.84
Analysts	Buy
Price Target	18.00 (+43.31%)
Earnings Date	Sep 8, 2026

About Revenio Group Oyj

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by vet...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 246
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: REG1V

Financial Performance

In 2025, Revenio Group Oyj's revenue was 109.85 million, an increase of 5.80% compared to the previous year's 103.82 million. Earnings were 17.41 million, a decrease of -5.87%.

Analyst Summary

According to 3 analysts, the average rating for REG1V stock is "Buy." The 12-month stock price target is €18.00, which is an increase of 43.31% from the latest price.

Price Target

€18.00

(43.31% upside)

Analyst Consensus: Buy